3ȸ '±¤µ¿ ¾ÏÇмú»ó' °­À±±¸-±èÈ£±Ù-ÀÓ¼®¾Æ ±³¼ö ¼ö»ó

¾Ï Ä¡·áºÐ¾ß ±âÃÊ-ÀÓ»ó ¿¬±¸¿¡ ¸¹Àº ±â¿©
´º½ºÀÏÀÚ: 2014³â06¿ù20ÀÏ 12½Ã31ºÐ

´ëÇѾÏÇÐȸ°¡ ¼±Á¤, ¼ö¿©ÇÏ´Â Á¦3ȸ '±¤µ¿ ¾ÏÇмú»ó' ¼ö»óÀÚ·Î °­À±±¸ ±³¼ö(¿ï»ê´ë ÀÇ°ú´ëÇÐ ³»°ú), ±èÈ£±Ù ±³¼ö(¿¬¼¼´ë ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç), ÀÓ¼®¾Æ ±³¼ö(¼­¿ï´ë ÀÇ°ú´ëÇÐ ³»°ú)°¡ ¼ö»óÇß´Ù.(»çÁø/Á·κÎÅÍ °­À±±¸-±èÈ£±Ù-ÀÓ¼®¾Æ ±³¼ö)

±¤µ¿ ¾ÏÇмú»óÀº ´ëÇѾÏÇÐȸ¿Í ±¤µ¿Á¦¾àÀÌ °øµ¿ Á¦Á¤ÇßÀ¸¸ç À̹øÀÌ 3¹ø°´Ù.

´ëÇѾÏÇÐȸ´Â 20ÀÏ ¼­¿ï ¼Ò°øµ¿ ·Ôµ¥È£ÅÚ¿¡¼­ ¿­¸° Á¦40ȸ ´ëÇѾÏÇÐȸ Á¤±âÃÑȸ¿¡¼­ °­À±±¸ ±³¼ö, ±èÈ£±Ù ±³¼ö, ÀÓ¼®¾Æ ±³¼ö¿¡°Ô Á¦3ȸ ±¤µ¿ ¾ÏÇмú»óÀ» ¼ö¿©Çß´Ù°í ¹àÇû´Ù.

ÀÌ »óÀº ¼öÁØ ³ôÀº SCI Àú³Î ȤÀº ºÐ¾ßº° SCI ³í¹®ÀÇ ºñÀ²ÀÌ ³ôÀº ÇÐȸÁö¿¡ ´ëÇѾÏÇÐȸÁö¸¦ ÀοëÇÑ ³í¹®À» ¹ßÇ¥ÇÑ ¿¬±¸ÀÚ, ±×¸®°í ´Ù¼öÀÇ SCI Àú³Î¿¡ ´ëÇѾÏÇÐȸÁö¸¦ ÀοëÇØ ¹ßÇ¥ÇÑ ¿¬±¸ÀÚ µî Ź¿ùÇÑ ¿¬±¸ ¼º°ú¸¦ ³½ ÀÇÇÐÀÚ¿¡°Ô ¼±Á¤, ¼ö¿©µÈ´Ù.

½É»ç´Â ´ëÇѾÏÇÐȸ »óÀÓÀ§¿øȸ°¡ ¸Ã¾Æ ÃÖÁ¾ ¼ö»óÀÚ¸¦ °áÁ¤ÇÑ´Ù.
¼ö»óÀÚ¿¡°Ô´Â »óÀå°ú ÇÔ²² »ó±Ý 500¸¸¿øÀÌ ¼ö¿©ÇÑ´Ù.

ÃÖ°í ¿µÇâ·ÂÁö¼ö(IF, Impact Factor) SCI Àú³ÎÀÇ Àӻ󿬱¸ ³í¹® ¹ßÇ¥ ºÎ¹®¿¡¼± °­À±±¸ ±³¼ö°¡ Lancet Oncol(IF 25.12)¿¡ ³í¹®(Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial)À» °ÔÀçÇß´Ù.

±âÃÊ¿¬±¸ ³í¹® ¹ßÇ¥ ºÎ¹®¿¡¼­´Â ±èÈ£±Ù ±³¼ö°¡ Clin Cancer Res(IF 7.837)¿¡ ³í¹®(Protein Kinase C-delta-Mediated Recycling of Active KIT in Colon Cancer)¿¡ ¹ßÇ¥Çß´Ù.

ÀÓ¼®¾Æ ±³¼ö´Â ¸ðµÎ 6ÆíÀÇ SCI Àú³Î¿¡ ´ëÇѾÏÇÐȸÁö¸¦ Àοë, ³í¹®À» °ÔÀçÇÔÀ¸·Î½á ±¹³» ÃÖ°í ±ÇÀ§ÀÇ ¾ÏÇÐȸÁö°¡ ¸í½Ç»óºÎÇÑ ±¹Á¦Àú³Î·Î µµ¾àÇϴµ¥ Å©°Ô ±â¿©Çß´Ù.

´ëÇѾÏÇÐȸ °ü°èÀÚ´Â “ÇÐȸ ⸳ 40ÁÖ³âÀ» ±â³äÇÏ´Â ÀÚ¸®¿¡¼­ ¾Ï Ä¡·áºÐ¾ßÀÇ ±âÃÊ-ÀÓ»ó ¿¬±¸¿¡ ¸¹Àº ±â¿©¸¦ ÇÑ È¸¿øµé¿¡°Ô ¶æ ±íÀº »óÀ» ¼ö¿©ÇÏ°Ô µÅ ±â»Ú´Ù”¸ç “ÇâÈÄ ½Éµµ ±íÀº ¿¬±¸°¡ ÁøÇàµÅ Çѱ¹ ÀÇÇÐÀÇ ±¹Á¦Àû À§»ó Á¤¸³¿¡ ±â¿©ÇÒ ¼ö ÀÖ±æ ±â´ëÇÑ´Ù"°í ÀüÇß´Ù.

 

 

 

 


ÀÌ ´º½ºÅ¬¸®ÇÎÀº BKT´º½º{www.bktimes.net}¿¡¼­ ¹ßÃéµÈ ³»¿ëÀÔ´Ï´Ù.